Vertex Pharmaceuticals
Registered Principal Details
Business Or Interest:
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative new medicines so people with serious diseases can lead better lives.
Lobbying Interests:
Engage on legislation that impacts access to innovative medicines and therapies; assist with disease awareness initiatives.
CEO Name:
Reshma Kewalramani
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative new medicines so people with serious diseases can lead better lives.
Lobbying Interests:
Engage on legislation that impacts access to innovative medicines and therapies; assist with disease awareness initiatives.
CEO Name:
Reshma Kewalramani
Contact
LB
Libby Brunsvold
50 Northern Avenue
Boston, MA 20001
(617) 961-7770
Libby_Brunsvold@vrtx.com
http://www.vrtx.com
50 Northern Avenue
Boston, MA 20001
(617) 961-7770
Libby_Brunsvold@vrtx.com
http://www.vrtx.com
Authorized Lobbyists
| Lobbyist Name | Exclusive Duties | Authorized On | Withdrawn On |
|---|
Lobbying Interests
Legislative Bills/Resolutions
Assembly Bill 103
Relating to: application of prescription drug payments to health insurance cost-sharing requirements.
Bill Text and History
3/18/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Relating to: application of prescription drug payments to health insurance cost-sharing requirements.
Bill Text and History
For
Notification Date3/18/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Assembly Bill 773
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
12/9/2023
First Communication Date
12/9/2023
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
For
Notification Date12/9/2023
First Communication Date
12/9/2023
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Assembly Joint Resolution 111
Relating to: observing February 29, 2024, as Rare Disease Day in Wisconsin.
Bill Text and History
2/3/2024
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Relating to: observing February 29, 2024, as Rare Disease Day in Wisconsin.
Bill Text and History
For
Notification Date2/3/2024
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Senate Bill 100
Relating to: application of prescription drug payments to health insurance cost-sharing requirements.
Bill Text and History
3/7/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Relating to: application of prescription drug payments to health insurance cost-sharing requirements.
Bill Text and History
For
Notification Date3/7/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Senate Bill 737
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
12/4/2023
First Communication Date
12/4/2023
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
For
Notification Date12/4/2023
First Communication Date
12/4/2023
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Senate Joint Resolution 102
Relating to: observing February 29, 2024, as Rare Disease Day in Wisconsin.
Bill Text and History
2/3/2024
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Relating to: observing February 29, 2024, as Rare Disease Day in Wisconsin.
Bill Text and History
For
Notification Date2/3/2024
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Topics Not Yet Assigned A Bill Or Rule Number
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to sickle disease awareness month.
Development, drafting or introduction of a proposal related to sickle disease awareness month.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to the treatment of sickle cell disease
Development, drafting or introduction of a proposal related to the treatment of sickle cell disease
Action Intended To Affect
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal Medicaid drug coverage process and procedure.
Development, drafting or introduction of a proposal Medicaid drug coverage process and procedure.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal related to the creation of a rare disease advisory council.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to the creation of a rare disease advisory council.
Development, drafting or introduction of a proposal related to the creation of a rare disease advisory council.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to treatment of cyclic fibrosis.
Development, drafting or introduction of a proposal relating to treatment of cyclic fibrosis.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
12/22/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Total Lobbying Effort
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total | |
|---|---|---|---|---|---|
| Total Lobbying Expenditures | 2023 January - June $24,000.00 |
2023 July - December $24,000.00 |
2024 January - June $0.00 |
2024 July - December $24,000.00 |
Total $72,000.00 |
| Total Hours Communicating | 2023 January - June 1.50 |
2023 July - December 0.00 |
2024 January - June 1.00 |
2024 July - December 0.00 |
Total 2.50 |
| Total Hours Other | 2023 January - June 22.00 |
2023 July - December 19.00 |
2024 January - June 5.50 |
2024 July - December 11.50 |
Total 58.00 |
Percent Allocation of Lobbying Effort
Legislative Bills/Resolutions
Relating to: application of prescription drug payments to health insurance cost-sharing requirements.
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June 25% |
2023 July - December 35% |
2024 January - June |
2024 July - December |
Total 21% |
Relating to: application of prescription drug payments to health insurance cost-sharing requirements.
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June 25% |
2023 July - December 35% |
2024 January - June |
2024 July - December |
Total 21% |
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June |
2023 July - December 20% |
2024 January - June 40% |
2024 July - December |
Total 12% |
Relating to: observing February 29, 2024, as Rare Disease Day in Wisconsin.
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June |
2023 July - December |
2024 January - June 10% |
2024 July - December |
Total 2% |
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June |
2023 July - December |
2024 January - June 40% |
2024 July - December |
Total 5% |
Budget Bill Subjects
No budget bill subjects found.
Administrative Rulemaking Proceedings
No administrative rulemaking proceedings found.
Topics Not Yet Assigned A Bill Or Rule Number
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June 10% |
2023 July - December |
2024 January - June |
2024 July - December |
Total 4% |
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June 20% |
2023 July - December |
2024 January - June |
2024 July - December 50% |
Total 17% |
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June 20% |
2023 July - December |
2024 January - June |
2024 July - December |
Total 8% |
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June |
2023 July - December 10% |
2024 January - June 10% |
2024 July - December 50% |
Total 14% |
Minor Efforts
No minor efforts found.
Other Matters
No other matters found.